ABT-510

DB05434InvestigationalSmall molecule

ABT-510 is a peptide mimetic of thrombospondin-1 (TSP-1), blocks angiogenesis in vitro and in vivo, and slows tumor growth. It is developed by Abbott Laboratories for the treatment of Solid...

Mechanism: ABT-510 is a synthetic peptide that mimics the anti-angiogenic activity of the naturally occurring protein, thrombospondin-1 (TSP-1). Angiogenesis is the process of new blood vessel formation. ABT-510 blocks the actions of multiple pro-angiogenic growth factors known to play a role in cancer related blood vessel growth, such as VEGF, bFGF, HGF, and IL-8. ABT-510 is the first compound with this mechanism of action to be studied.
Curator reviewed
Primary indication: Investigated for use/treatment in lymphoma (unspecified), melanoma, and solid tumors.Curator reviewed
Formula / weight: C₄₆H₈₃N₁₃O₁₁ · 994.2317 g/mol (avg)
Code names: ABT-510

Resolves to

Compound

UNIICRR8E37XOBCAS251579-55-2ChEMBLCHEMBL386115PubChem6918562

Structure

InChIKeyRIWLPSIAFBLILR-WVNGMBSFSA-NSMILES

CCC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)CN(C)C(C)=O)C(C)C)[C@@H](C)CC)[C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC

Targets

P07996THBS1P09038FGF2P14210HGFP15692VEGFAP10145CXCL8

What you can answer from here — as of January 29, 2025

5Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

8Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with ABT-510, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account